Abstract
Alimentary Pharmacology & TherapeuticsVolume 27, Issue 6 p. 528-529 Free Access Corrigenda This article corrects the following: Review article: appropriate use of corticosteroids in Crohn’s disease P. M. IRVING, R. B. GEARRY, M. P. SPARROW, P. R. GIBSON, Volume 26Issue 3Alimentary Pharmacology & Therapeutics pages: 313-329 First Published online: May 25, 2007 First published: 20 February 2008 https://doi.org/10.1111/j.1365-2036.2008.03608_1.xAboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat In Ref.1, Figure 1 contained an error in which Finland was shown in yellow colour (availability of infliximab, 0–25%), where it should have been shown in blue colour (availability of infliximab, 76–100%). The corrected Figure 1 is printed below. Figure 1Open in figure viewerPowerPoint Gastroenterologists’ perceptions of availability of infliximab in their own countries. As the information was not made available by the manufacturer or distributor of infliximab, gastroenterologists around the world were contacted and asked to estimate what proportion of their country’s population had access to infliximab to induce remission for active Crohn’s disease. African gastroenterologists provided data for more than one country. References 1 Irving PM, Gearry RB, Sparrow MP, Gibson PR. Review article: appropriate use of corticosteroids in Crohn’s disease. Aliment Pharmacol Ther 2007; 26: 313– 29. 2 Campisi G, Di Liberto C, Iacono G, et al. Oral pathology in untreated coelic disease. Aliment Pharmacol Ther 2007; 26: 1529– 36. 3 Manolakopoulos S, Bethanis S, Koutsounas S, et al. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther 2008; 27: 266– 73. 4 Spaander VM, Van Buuren HR, Janssen HL. Review article: the management of non-cirrhotic non-malignant portal vein thrombosis and concurrent portal hypertension in adults. Aliment Pharmacol Ther 2007; 26 (Suppl. 2): 203– 9. Volume27, Issue6March 2008Pages 528-529 FiguresReferencesRelatedInformation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
